Multiple Myeloma: Myeloablative Therapy with Autologous Stem Cell Support versus Chemotherapy: A Meta-analysis
Anticancer Research, 05/18/2012
Evidence Based Medicine
Faussner F et al. – Although there is only a trend of overall survival (OS) benefit with high–dose chemotherapy (HDT), it is currently still the first line treatment. Additional data from ongoing clinical trials and new studies using novel agents such as thalidomide, lenalidomide and bortezomib are warranted to finally evaluate the role of HDT in the treatment management of patients with newly diagnosed multiple myeloma (MM).